The Disciplinary Board criticized the pharmacist for not directly explaining how to safely use the product. In response to pharmacists' outcry over this and other recent harsh penalties, the Board trustee resigned.
Despite the hype surrounding GLP-1 receptor agonists, a significant proportion of patients discontinue treatment after a few months, reducing the chances of long-term benefits.